Category: Other investment-impacting news

1. Summary of the news

A new study published in JAMA Psychiatry finds that antipsychotic prescribing among U.S. adults aged 65 and older has risen sharply over the past decade. Usage increased from 2.67 per 100 people in 2015 to 4.05 per 100 in 2024, based on prescription claims data covering more than 8 million older adults nationwide.

The increase is driven largely by long-term care pharmacies and longer-duration use, while prescriptions written by psychiatrists declined over the same period.

2. Background context

Antipsychotics are commonly prescribed for schizophrenia and bipolar disorder, but in older adults they are frequently used off-label to manage behavioral symptoms associated with dementia and cognitive impairment. These drugs carry well-documented risks for seniors, including falls, cardiovascular events, and increased mortality, making prescribing trends a longstanding concern for regulators and clinicians.

The authors suggest the data reflect a rise in chronic conditions and cognitive decline among older Americans, alongside gaps in access to non-pharmacologic behavioral and mental health interventions.

3. Market impact (healthcare focus)

  • Long-term care (LTC): Increased reliance on medication signals staffing and care-model pressures in nursing homes and assisted living facilities.

  • Behavioral health services: Underutilization of psychiatrists and behavioral therapies points to supply constraints and reimbursement misalignment.

  • Regulatory exposure: Higher antipsychotic use in LTC settings may invite renewed scrutiny from CMS and state regulators focused on quality-of-care metrics.

  • Pharmacy services: LTC pharmacies are becoming increasingly central players in geriatric medication management.

4. Relevance for healthcare private-capital investors

For private-capital healthcare investors, the study highlights several actionable themes:

  • Care-model opportunity: Strong demand for non-pharmacologic dementia care, behavioral health integration, and staff training platforms in long-term care.

  • Risk mitigation plays: Technologies that reduce inappropriate prescribing—clinical decision support, monitoring, and outcomes tracking—may see growing adoption.

  • Demographic tailwinds: The aging population continues to drive utilization growth, but quality and compliance will increasingly determine which providers and vendors win.

Bottom line: Rising antipsychotic use among older adults underscores structural gaps in geriatric mental health care—creating both regulatory risk for incumbents and compelling opportunities for investors backing safer, more holistic care solutions.

‍